Downie T R, Hows J M, Gore S M, Bradley B A, Howard M R
Department of Transplantation Sciences, University of Bristol, Southmead Health Services, Westbury-on-Trym, UK.
Bone Marrow Transplant. 1995 Apr;15(4):499-503.
Unrelated donor bone marrow transplantation is increasingly used to treat haemopoietic disorders where no HLA-identical sibling is available. The International Marrow Unrelated Search and Transplant Study has collected core data on consecutive unrelated donor BMT (UD-BMT) and HLA-identical sibling donor BMT (ID-BMT) performed in 46 participating centres world-wide between March 1989 and February 1993. Eighteen UD-BMT were performed in the first 6-month period in 14 participating centres, while in the last period there were 103 UD-BMT in 46 centres. The percentage of BMT recipients with the following diagnoses were: bone marrow failure UD-BMT 15% and ID-BMT 11%; AML 13% and 27%; ALL 18% and 17%; CML 48% and 31%; and other diseases 7% and 14%. Thirty-eight per cent of UD-BMT recipients had advanced disease compared with only 23% of ID-BMT recipients. Thirty six per cent of UD-BMT compared with 21% of ID-BMT recipients were under 16 years old. More extreme differences in pre-transplant clinical characteristics between UD and ID-BMT recipients were found when diagnosis and stage of disease were considered together. This survey indicates how UD and ID-BMT are currently used in the treatment of haematological disease; however, longer follow-up is required to assess the value of UD-BMT in the management of patients with bone marrow disorders.
在没有 HLA 匹配同胞供者的情况下,无关供者骨髓移植越来越多地用于治疗造血系统疾病。国际无关供者骨髓检索与移植研究收集了 1989 年 3 月至 1993 年 2 月期间全球 46 个参与中心进行的连续无关供者骨髓移植(UD - BMT)和 HLA 匹配同胞供者骨髓移植(ID - BMT)的核心数据。在最初的 6 个月期间,14 个参与中心进行了 18 例 UD - BMT,而在最后一个阶段,46 个中心有 103 例 UD - BMT。接受以下诊断的骨髓移植受者百分比分别为:骨髓衰竭 UD - BMT 为 15%,ID - BMT 为 11%;急性髓系白血病(AML)为 13%和 27%;急性淋巴细胞白血病(ALL)为 18%和 17%;慢性髓系白血病(CML)为 48%和 31%;其他疾病为 7%和 14%。38%的 UD - BMT 受者患有晚期疾病,而 ID - BMT 受者仅为 23%。36%的 UD - BMT 受者年龄在 16 岁以下,而 ID - BMT 受者为 21%。当综合考虑疾病诊断和分期时,UD 和 ID - BMT 受者在移植前临床特征方面存在更显著差异。这项调查表明了目前 UD - BMT 和 ID - BMT 在血液系统疾病治疗中的应用情况;然而,需要更长时间的随访来评估 UD - BMT 在骨髓疾病患者管理中的价值。